Pelthos Therapeutics Inc

Insider buying at Pelthos Therapeutics shows board confidence amid volatile stock, a reverse split, and pending CT2000 trial results.

Insider buying by board member Friedberg signals confidence in Pelthos’s early-stage eye‑drop therapy, hinting at potential upside once clinical data are released.